FDA Class II Recall: Unichem's Bisoprolol Fumarate/Hydrochlorothiazide Tablets Pulled Over Nitrosamine Impurities and cGMP Deviations
Unichem Pharmaceuticals (USA), Inc. has initiated a Class II recall for Bisoprolol Fumarate and Hydrochlorothiazide tablets due to N-Nitroso Bisoprolol impurity specification failures and cGMP deviations. This impacts US and Puerto Rico markets, demanding immediate action from procurement and regulatory teams to manage supply chain disruptions and ensure patient safety, highlighting ongoing industry challenges with nitrosamine control.
FDA Class II Recall: Unichem's Bisoprolol Fumarate/Hydrochlorothiazide Due to Nitrosamine Impurities
On January 21, 2026, Unichem Pharmaceuticals (USA), Inc., based in East Brunswick, NJ, initiated a voluntary Class II recall for specific lots of its Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg. This action, identified by FDA recall number D-0301-2026, directly impacts the US Nationwide and Puerto Rico markets. The primary reason cited for this recall is the product's failure to meet N-Nitroso Bisoprolol impurity specification limits, coupled with broader cGMP (current Good Manufacturing Practice) deviations. The affected product, manufactured by UNICHEM LABORATORIS LTD. in Pilerne Ind. Estate, Bardez, Goa 403 511, India, is distributed under NDC 29300-187-01, among others, and includes lot # GBHL24005A with an expiration date of September 2026. For procurement directors, this means immediate cessation of sourcing and distribution of the identified lot. Regulatory affairs heads must ensure compliance with recall procedures and prepare for potential increased scrutiny on other products sourced from this manufacturer. Supply chain VPs face the immediate challenge of managing reverse logistics and securing alternative supplies for this combination antihypertensive drug.
Immediate Commercial Implications of cGMP Deviations for Pharmaceutical Procurement
The identification of cGMP deviations alongside impurity failures for Unichem's Bisoprolol Fumarate and Hydrochlorothiazide tablets signals a critical quality control lapse at the manufacturing facility in Goa, India. For procurement directors, this event underscores the inherent risks associated with supplier quality management, particularly for essential human prescription drugs. The Class II classification indicates that the product's use may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, but the commercial impact remains significant. Companies sourcing this product (ANDA079106) must immediately quarantine existing stock from lot GBHL24005A and verify the compliance status of other lots or products from Unichem. Regulatory affairs teams must assess the potential for broader regulatory action against the manufacturer and ensure their internal quality systems can detect and respond to similar issues. Business development executives should evaluate the potential for market share shifts as competitors with robust quality systems may gain an advantage during this disruption.
Supply Chain Disruption for Bisoprolol Fumarate and Hydrochlorothiazide in US and PR Markets
The US Nationwide and Puerto Rico distribution pattern of the recalled Bisoprolol Fumarate and Hydrochlorothiazide tablets means a significant portion of the market is affected. Supply chain VPs must prioritize rapid identification and removal of the implicated product from their distribution networks. The absence of specific alternative suppliers in current intelligence highlights the immediate challenge for companies reliant on Unichem for this particular molecule combination. Qualifying new suppliers for a dual-API product like Bisoprolol Fumarate and Hydrochlorothiazide can be a lengthy process, often taking 12-18 months, involving extensive audits, analytical testing, and regulatory submissions. This recall, therefore, creates a potential short-to-medium term supply gap for this oral hypertension treatment. Procurement teams should initiate urgent outreach to other known manufacturers of similar products to assess availability and qualification timelines, while regulatory affairs must manage the implications for product registration and market continuity.
Heightened Regulatory Scrutiny on Nitrosamine Impurities: A Broader Industry Challenge
The specific failure to meet N-Nitroso Bisoprolol impurity specification limits places this recall within a broader industry trend of heightened regulatory scrutiny on nitrosamine contaminants. The FDA, along with other global health authorities, has consistently emphasized the need for pharmaceutical manufacturers to conduct thorough risk assessments for nitrosamine formation and implement robust control strategies. This event serves as a stark reminder for regulatory affairs heads that ongoing vigilance and proactive measures are essential. Companies must ensure their analytical methods are sensitive enough to detect these impurities at very low levels and that their manufacturing processes are designed to minimize their formation. For business development executives, demonstrating a strong commitment to impurity control and quality assurance can be a significant competitive differentiator in a market increasingly sensitive to product safety. This incident reinforces the FDA's unyielding focus on product quality and patient safety, particularly concerning genotoxic impurities.
Unichem's Remediation Path and Future Compliance Outlook
With the recall status listed as 'Ongoing' as of February 11, 2026, Unichem Pharmaceuticals (USA), Inc. and its manufacturing affiliate, UNICHEM LABORATORIS LTD. in India, face a critical period of remediation. The firm is expected to conduct a comprehensive investigation into the root causes of both the cGMP deviations and the N-Nitroso Bisoprolol impurity failures. This will likely involve process re-validation, enhanced quality control measures, and potentially significant capital investment in facility upgrades or equipment. For procurement directors, this situation necessitates a re-evaluation of Unichem as a long-term supplier, considering the potential for future supply interruptions or additional regulatory actions. Regulatory affairs teams must monitor Unichem's corrective and preventive actions (CAPA) closely, as the FDA may conduct follow-up inspections. The outcome of these remediation efforts will significantly influence Unichem's ability to market and distribute other products in the US, impacting its overall commercial viability and market access for its entire portfolio.